Ann Arbor-based biopharmaceutical lab Avomeen has announced the hiring of Hashim Ahmed as its new head of formulation and manufacturing.
Ahmed has more than 25 years of experience in the biopharmaceutical and contract development and manufacturing organization industries, most recently serving as the managing director at QLife Pharma. In his new position he will work with biopharmaceutical clients that are navigating both small- and large-molecule product development life cycles.
“Hashim brings a wealth of knowledge and expertise in manufacturing science and technology, product development, and CMC,” says Mark Harvill, CEO of Avomeen. “His blend of leadership, experience in biopharma companies and CDMOs, and small-molecule and large-molecule expertise will help us fortify and expand this business segment to include more services.”
Ahmed has held leadership positions with companies such as Dr. Reddy’s Laboratories, GSK-Stiefel, and Hoffmann-La Roche Inc., as well as serving as a consultant for various biopharmaceutical companies. Holding 21 patents on drug formulation and process in the U.S. and having more than 30 presentations and publications of his work, his expertise covers small and large molecules, orals, controlled-modified release formulations, and parenterals dosages.
A World Health Organization Fellow and member of other professional organizations, Ahmed has built his career as a pharmaceutical product development and regulatory expert. He received his bachelor’s degree in pharmacy from the University of Khartoum in Sudan and his doctorate degree in pharmaceutical sciences from the University of Bath-England-UK. He is a member of professional organizations including the American Association of Pharmaceutical Scientists, Royal Pharmaceutical Society of Great Britain, Sudanese Medical Society, and Sudanese Pharmaceutical Society.